Author:
Sobhy Amr,K. Eldin Doaa M.,Zaki Hany V.
Abstract
Background and Aims:
In our study, we investigated the effectiveness of intravenous milrinone in life-threatening bronchial asthma as compared to conventional treatment.
Methods:
Fifty patients aged 18-50 years, presenting with life-threatening asthma were enrolled in a Randomised Controlled Trial (RCT). They were randomly allocated into Group C (25 patients): who received the standard pharmacotherapy and placebo, and Group M (25 patients): who in addition to the standard therapy, received 25 μg milrinone as an initial slow IV bolus diluted in 10 ml of normal saline. The following data were recorded: PEFR (Peak Expiratory Flow Rate) expressed as a percentage of the patient’s previous value, Respiratory Rate (RR), MABP (Mean Arterial Blood Pressure), arterial blood gases, and the number of patients requiring mechanical ventilation. Differences between groups were tested using Analysis of Variance (ANOVA) for quantitative variables with post hoc using the Least Significant Difference (LSD) test, and Chi square test for categorical variables.
Results:
Group M showed marked improvement in PEFR that was highly significant (P < 0.001) 10 min after injection and significant after one hour from the start of treatment in comparison to Group C. There was also an improvement in RR and PO2 that was significant in group M. Milrinone was associated with a reduction in MABP only after 10 min from injection, and showed a statistically significant decrease in the number of patients requiring mechanical ventilator support (P ˂ 0.05).
Conclusion:
Milronine is a promising agent as a rescue drug in the treatment of life-threatening bronchial asthma.
Publisher
Bentham Science Publishers Ltd.
Subject
Anesthesiology and Pain Medicine
Reference13 articles.
1. Beute J.
Emergency treatment of status asthmaticus with enoximone.
Br J Anaesth
2014;
112
(6)
: 1105-8.
2. Asthma and Allergy Foundation of America.
Available from
http://www.aafa.org
2018.
3. Fujimura M, Kamio Y, Myou S, Hashimoto T, Matsuda T.
Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma.
Int Arch Allergy Immunol
1997;
114
(4)
: 379-84.
4. Katzung BG, Parmley WW.
Drugs used in Heart Failure.
Basic and Clinical Pharmacology 10th ed.
2007;
198-210.
5. British Guideline on the Managament of Asthma.
May 2008 revised
2014.
Available from http://www.sign.ac.uk/pdf/sign101.pdf
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献